These are the mid-caps that could perform best during ‘downturn’ regimes – BofA
Seeking Alpha News (Wed, 18-Sep 2:00 PM ET)
Cencora cut to Neutral at BofA; risks to Walgreens, Cigna contracts cited
Seeking Alpha News (Wed, 18-Sep 11:34 AM ET)
Cencora: A Balanced Future Outlook Justifies Hold Rating Amid Modest Growth Projections
TipRanks (Fri, 13-Sep 6:56 AM ET)
Frazier Healthcare Partners Adds Highly Experienced Pharma Executive to Growth Buyout Team
Business Wire (Tue, 10-Sep 8:00 AM ET)
Cencora Elects Frank Clyburn to Its Board of Directors
Business Wire (Thu, 15-Aug 7:30 AM ET)
Cencora Announces Common Share Repurchase From Walgreens Boots Alliance
Business Wire (Thu, 1-Aug 6:17 PM ET)
Walgreens Boots Alliance Sells Shares of Cencora for Approximately $1.1 Billion of Proceeds
Business Wire (Thu, 1-Aug 6:08 PM ET)
Cencora Reports Fiscal 2024 Third Quarter Results
Business Wire (Wed, 31-Jul 6:30 AM ET)
Globe Newswire (Mon, 8-Jul 8:35 AM ET)
Cencora Announces Date and Time for Third Quarter Fiscal 2024 Earnings Release
Business Wire (Fri, 5-Jul 4:15 PM ET)
Cencora is one of three domestic leading pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health constitute over 90% of the us pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
Cencora trades on the NYSE stock market under the symbol COR.
As of September 18, 2024, COR stock price declined to $228.48 with 2,135,684 million shares trading.
COR has a beta of 0.09, meaning it tends to be less sensitive to market movements. COR has a correlation of 0.00 to the broad based SPY ETF.
COR has a market cap of $44.78 billion. This is considered a Large Cap stock.
Last quarter Cencora reported $74 billion in Revenue and $3.34 earnings per share. This beat revenue expectation by $761 million and exceeded earnings estimates by $.12.
The top ETF exchange traded funds that COR belongs to (by Net Assets): RAYD, VTI, VOO, VO, SPY.
COR has outperformed the market in the last year with a return of +29.3%, while the SPY ETF gained +27.8%. However, in the most recent history, COR shares have underperformed the stock market with its stock returning -2.4% in the last 3 month period and -6.3% for the last 2 week period, while SPY has returned +2.9% and +1.7%, respectively.
COR support price is $231.70 and resistance is $237.36 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that COR stock will trade within this expected range on the day.